Pharmaceuticals, Biotechnology and Life Sciences
HighTide is expecting to finalize the data analysis and is preparing submissions for presentation and peer-reviewed publication.
Schreiner MediPharm has developed a compact Booklet-Label for a needle protection system used in an international phase III clinical trial conducted by pharmaceutical corporation Sanofi.
GSK expects gross proceeds from the divestment to be £3.4 billion and net proceeds from the divestment to be £2.9 billion.
Sanofi and Regeneron plan to submit this year their product Libtayo, which has shown in a pivotal trial with certain patients with advanced basal cell carcinoma, that it has meaningful and durable responses.
Centogene said Tuesday it will expand its testing efforts for the novel coronavirus, or COVID-19, from previously testing in Germany’s Mecklenburg-Western Pomerania region, to now offering its extensively validated SARS-CoV-2 RT-PCR testing to the rest of the world.
Shionogis’ Fetcroja (cefiderocol) in the end of April 2020 received European Commission (EC) marketing authorisation for the treatment of infections due to aerobic Gram-negative bacteria in adults with limited treatment options.
Certain people need to take additional energy in the form of specific supplements, but they are not a substitute for a balanced healthy diet.
Mylan and Biocon have launched Fulphila, a biosimilar to Neulasta (pegfilgrastim), as it was approved by Health Canada to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.
Incyte last week named new Canada Biosciencess head, announcing establishing key development and commercialization capabilities in preparation for potential launches of multiple products in the near future.
Sanofi believes its brain-penetrant BTK inhibitor shows promise for reducing both neuroinflammation and neurodegeneration, markers of disability progression in people living with MS.